Search results for "steatohepatitis"

showing 10 items of 134 documents

Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome

2010

NASH (non-alcoholic steatohepatitis) is considered the hepatic manifestation of the metabolic syndrome (MS). We aimed to analyze lipid, carbohydrate, and iron metabolism in NASH.37 patients with MS (17 M/20 F, 51+/-15 years), elevated transaminases; 25 patients had histologically proven NASH (NAS score≥5), 12 patients had toxic background (nonNASH). 37 age, sex, BMI-matched healthy controls. Lipid variables, LDL-subfractions, iron, ferritin, transferrin (T), transferrin saturation (TS), and hepcidin (H) were measured in patients/controls. Oral glucose tolerance tests were performed.NASH patients with steatosis gr. 2 and 3 (33% hepatic fat) had higher sd-LDL (mg/dl) concentrations than patie…

AdultMalemedicine.medical_specialtyIronInsulin resistanceHepcidinsNon-alcoholic Fatty Liver DiseaseInternal medicineInternal MedicinemedicineHumansInsulinAgedMetabolic Syndromechemistry.chemical_classificationGlucose tolerance testC-Peptidemedicine.diagnostic_testTransferrin saturationbusiness.industryTransferrinnutritional and metabolic diseasesLipid metabolismCholesterol LDLGlucose Tolerance TestMiddle AgedLipid Metabolismmedicine.diseasedigestive system diseasesFatty LiverEndocrinologychemistryTransferrinFerritinsMetabolomeCarbohydrate MetabolismFemaleMetabolic syndromeSteatosisSteatohepatitisbusinessAntimicrobial Cationic PeptidesEuropean Journal of Internal Medicine
researchProduct

High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steato…

2011

Abstract Background and aim To investigate the hepatic expression of retinol-binding protein-4 (RBP4) in chronic hepatitis C (CHC) and nonalcoholic steatohepatitis (NASH) patients, and its association with biochemical and histological patterns of liver damage. Materials and methods Sixty-six genotype 1 CHC and 32 NASH patients were tested for hepatic RBP4 expression. Liver expression at immunostaining was scored as 0 (slight), 1 (mild), 2 (moderate), and 3 (intense). In addition, the mRNA and the quantitative protein expressions of RBP4 were tested by PCR and by western blot, respectively, in 12 NASH and 28 CHC patients. Twelve subjects undergoing elective cholecystectomy served as controls…

AdultMalemedicine.medical_specialtyLogistic ModelFibrosiHepatitis C virusInflammationSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexWestern blotFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineGenotypeMedicineHumansAge FactorRNA MessengerHEPATIC STEATOSISRetinol binding protein 4Settore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbiologyNONALCOHOLIC STEATOHEPATITISbusiness.industryGastroenterologyAge FactorsHEPATITIS C VIRUSHepatitis C ChronicMiddle Agedmedicine.diseaseFibrosisFatty LiverLogistic Modelsbiology.proteinmedicine.symptomSteatosisInsulin ResistanceWaist CircumferenceRetinol binding protein-4businessRetinol-Binding Proteins PlasmaImmunostainingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Regulation of microRNAs and their role in liver development, regeneration and disease

2013

Abstract Since their discovery more than a decade ago microRNAs have been demonstrated to have profound effects on almost every aspect of biology. Numerous studies in recent years have shown that microRNAs have important roles in development and in the etiology and progression of disease. This review is focused on microRNAs and the roles they play in liver development, regeneration and liver disease; particularly chronic liver diseases such as alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, viral hepatitis and primary liver cancer. The key microRNAs identified in liver development and chronic liver disease will be discussed together with, where pos…

Alcoholic liver diseaseLiver DiseasesFatty liverCell BiologyDiseaseBiologyBioinformaticsmedicine.diseaseChronic liver diseaseBiochemistryLiver RegenerationMicroRNAsLiver diseaseGene Expression RegulationLivermicroRNAmedicineAnimalsHumansSteatohepatitisViral hepatitisThe International Journal of Biochemistry & Cell Biology
researchProduct

The role of morbid obesity in the promotion of metabolic disruptions and non-alcoholic steatohepatitis by Helicobacter Pylori

2016

Background Helicobacter pylory (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist. Material and methods Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 su…

Blood GlucoseMalePhysiologyBiopsylcsh:MedicineType 2 diabetesPathology and Laboratory MedicineBiochemistryGastroenterologyLiver diseaseEndocrinology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceImmune ResponseMultidisciplinarymedicine.diagnostic_testLiver DiseasesFatty liverMiddle AgedObesity MorbidPhysiological ParametersLiver biopsyCarbohydrate MetabolismFemale030211 gastroenterology & hepatologyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersImmunologySurgical and Invasive Medical ProceduresGastroenterology and HepatologyHelicobacter Infections03 medical and health sciencesSigns and SymptomsInsulin resistanceDiagnostic MedicineInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansObesityInflammationHelicobacter pyloriEndocrine Physiologybusiness.industryBody Weightlcsh:RBiology and Life Sciencesmedicine.diseaseImpaired fasting glucoseMorbid ObesityFatty LiverCross-Sectional StudiesMetabolismEndocrinologyDiabetes Mellitus Type 2Metabolic Disorderslcsh:QInsulin ResistanceSteatohepatitisbusiness
researchProduct

Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disea…

2015

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has been associated with increased cardiovascular risk, including coronary artery disease and cardiac dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a new cardiometabolic risk factor. We tested the correlation between epicardial fat, alterations in cardiac geometry and function, and severity of liver damage, in patients with biopsy-proven NAFLD. Methods The anthropometric, biochemical and metabolic features were recorded in 147 consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was measured by echocardiography. Results Epicardial fat was higher in patients w…

Cardiac function curveAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaStatistics as TopicDiastoleEPICARDIAL FATSettore MED/08 - Anatomia PatologicaSeverity of Illness IndexCoronary artery diseaseLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNASH; NAFLD; EPICARDIAL FAT; CARDIAC DYSFUNCTION;Internal medicineNAFLDmedicineHumansSettore MED/12 - GastroenterologiaEjection fractionHepatologybusiness.industryFatty liverNASHHeartMiddle Agedmedicine.diseaseEndocrinologyLiverCardiovascular DiseasesEchocardiographyCardiologyFemaleSteatohepatitisbusinessPericardiumCARDIAC DYSFUNCTION
researchProduct

PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.

2013

Background and Aim To evaluate if the presence of carotid atherosclerosis in patients with NAFLD, could be related to gene variants influencing hepatic fat accumulation and the severity of liver damage. Methods We recorded anthropometric, metabolic and histological data(Kleiner score) of 162 consecutive, biopsy-proven Sicilian NAFLD patients. Intima-media thickness(IMT), IMT thickening(IMT≥1 mm) and carotid plaques(focal thickening of >1.3 mm at the level of common carotid artery) were evaluated using ultrasonography. IL28B rs12979860 C>T, PNPLA3 rs738409 C>G, GCKR rs780094 C>T, LYPLAL1 rs12137855 C>T, and NCAN rs2228603 C>T single nucleotide polymorphisms were also assessed. The results we…

Carotid Artery DiseasesMalePathologylcsh:MedicineGastroenterology0302 clinical medicinePolymorphism (computer science)Non-alcoholic Fatty Liver DiseaseRisk FactorsGenotypeCommon carotid arterylcsh:ScienceATEROSCLEROSI0303 health sciencesMultidisciplinaryNONALCOHOLIC STEATOHEPATITISFatty liverMiddle Aged3. Good healthCarotid ArteriesCohortcardiovascular system030211 gastroenterology & hepatologyFemaleResearch ArticleAdultmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesmedicine.arteryDiabetes mellitusInternal medicinemedicineHumansClinical significancecardiovascular diseasesAllelesGenetic Association StudiesPNPLA3030304 developmental biologyAgedNAFLD PNPLA3 ATHEROSCLEROSISbusiness.industrylcsh:RMembrane ProteinsLipasemedicine.diseaseFatty Liverlcsh:Qbusiness
researchProduct

Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation.

2015

Nonalcoholic fatty liver disease (NAFLD) is defined by excessive triglycerides (TGs) accumulation in the liver (>5% of hepatocytes histologically) in the absence of alcohol excess. The NAFLD ranges from simple steatosis to steatohepatitis and cirrhosis. The NAFLD and nonalcoholic steatohepatitis (NASH) are now the number one cause of liver disease in Western countries. The prevalence of NAFLD is increasing but is underreported, and the epidemiology and demographic characteristics vary worldwide. The prevalence is increasing because of the rising occurrence of obesity and type 2 diabetes (T2DM); in fact, NAFLD is considered as the hepatic manifestation of metabolic syndrome (MetS). Nonalcoho…

Carotid Artery Diseasesmedicine.medical_specialtyVery low-density lipoproteinLipoproteins//purl.org/becyt/ford/3.3 [https]Risk FactorsInternal medicineNonalcoholic fatty liver diseasemedicinePrevalenceHumansInflammationAdiponectinbusiness.industryFatty liverNon Alcoholic Fatty Liver Diseasenutritional and metabolic diseasesmedicine.diseasedigestive system diseasesFatty LiverOxidative StressEndocrinologyCardiovascular DiseasesDisease Progression//purl.org/becyt/ford/3 [https]Hepatic lipaseMetabolic syndromeSteatohepatitisInsulin ResistanceCardiology and Cardiovascular MedicinebusinessBiomarkersLipoproteinAngiology
researchProduct

Microesferas de ácido poliláctico marcadas con 166Ho. Una alternativa frente a las de 90Y en el tratamiento del carcinoma hepático mediante radioembo…

2021

Los tumores hepáticos constituyen un importante problema de salud a nivel mundial que en multitud de ocasiones va asociado a patologías previas y factores de riesgo como las hepatitis víricas B y C, el consumo excesivo de alcohol y el aumento de casos de esteatohepatitis no alcohólica, cada vez más relevante en los países industrializados.En hepatocarcinomas no susceptibles de resección quirúrgica, la braquiterapia se está mostrando muy eficaz frente a la quimioterapia sistémica y transarterial, por lo que se desarrollan nuevos tratamientos locorregionales mínimamente invasivos y con menor toxicidad.La radioembolización hepática es una forma de braquiterapia consistente en la administración…

Chemotherapymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentBrachytherapyMagnetic resonance imagingViral hepatitis bmedicine.diseaseLower energyMicrospheremedicineHigh dosesSteatohepatitisbusinessNuclear medicineNereis. Interdisciplinary Ibero-American Journal of Methods, Modelling and Simulation.
researchProduct

Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients

2022

nessuno

Diabetes Mellitus Type 1EndocrinologyNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismInternal MedicineHumansObesityCardiometabolic risk Diabetes mellitus type 1 Metabolic syndrome Nonalcoholic Nonalcoholic fatty liver disease Obesity SteatohepatitisJournal of Diabetes and its Complications
researchProduct

Liver fibrosis: Common mechanisms and antifibrotic therapies

2015

Liver fibrosis and in particular cirrhosis have become major endpoints in clinical trials of patients with chronic liver diseases. Here, viral hepatitis, alcoholic and non-alcoholic steatohepatitis have become the major etiologies. We have made great progress in our understanding of the mechanisms and the cell biology of liver fibrosis and have already made the transition from preclinical testing of antifibrotic agents and strategies towards clinical translation. There continues to be an urgent need for specific antifibrotic therapies, despite the advent of highly potent antiviral agents that can even induce regression of advanced fibrosis. This review addresses central mechanisms and cells…

Diagnostic ImagingLiver CirrhosisCirrhosisHepatologybusiness.industryLiver fibrosisGastroenterologyAdaptive Immunitymedicine.diseaseBioinformaticsAcquired immune systemImmunity InnateClinical trialBiomarkerFibrosisImmunologymedicineAnimalsHumansSteatohepatitisViral hepatitisbusinessBiomarkersClinics and Research in Hepatology and Gastroenterology
researchProduct